Activation of T cells by carbamazepine and carbamazepine metabolites.
about
Update on Advances in Research on Idiosyncratic Drug-Induced Liver InjuryIdiosyncratic adverse drug reactions: current conceptsDrug reaction with Eosinophilia and Systemic Symptoms (DRESS) / Drug-induced Hypersensitivity Syndrome (DIHS): a review of current conceptsThe Absence of CYP3A5*3 Is a Protective Factor to Anticonvulsants Hypersensitivity Reactions: A Case-Control Study in Brazilian SubjectsButyrophilin 3A1 plays an essential role in prenyl pyrophosphate stimulation of human Vγ2Vδ2 T cellsIs the drug-induced hypersensitivity syndrome (DIHS) due to human herpesvirus 6 infection or to allergy-mediated viral reactivation? Report of a case and literature review.Metabolism considerations for kinase inhibitors in cancer treatmentIn silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteersImmunological principles of T-cell-mediated adverse drug reactions in skin.Drug antigenicity, immunogenicity, and costimulatory signaling: evidence for formation of a functional antigen through immune cell metabolism.Delayed drug hypersensitivity: models of T-cell stimulationDelayed drug hypersensitivity reactions - new concepts.Immune mediation of hypersensitivity adverse drug reactions: implications for therapy.In vitro testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review.Pharmacogenetics of toxic epidermal necrolysis.Skin manifestations of drug allergy.Regioselective biotransformation of CNS drugs and its clinical impact on adverse drug reactions.Investigative safety science as a competitive advantage for Pharma.Anticonvulsant hypersensitivity syndrome: an update.T-cell receptor and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: understanding a hypersensitivity reaction.HLA and pharmacogenetics of drug hypersensitivity.The generation, detection, and effects of reactive drug metabolites.Are drug metabolites able to cause T-cell-mediated hypersensitivity reactions?Stevens-johnson syndrome induced by carbamazepine treatment in a patient who previously had carbamazepine induced pruritus - a case report -.Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways.Oral exposure to immunostimulating drugs results in early changes in innate immune parameters in the spleen.Mechanisms involved in the Abacavir-mediated hypersensitivity syndrome.Avidity determines T-cell reactivity in abacavir hypersensitivity.Stevens-Johnson syndrome induced by the cross-reactivity between teicoplanin and vancomycin.Carbamazepine, a beta-cell protecting drug, reduces type 1 diabetes incidence in NOD mice.Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury.Association of ABCB1, CYP3A4, EPHX1, FAS, SCN1A, MICA, and BAG6 polymorphisms with the risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Chinese Han patients with epilepsy.Personalized medicine for HLA-associated drug-hypersensitivity reactionsResponse 2 to pharmacogenetic screening to prevent carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome: a critical appraisal
P2860
Q26779078-643960FA-D02C-4CAC-A248-232359EAE9E0Q26824391-E22E3CEF-487E-454B-AF29-5348595BF3D0Q27030788-7FC5F90D-B2E8-4E0B-BAAD-BE72C597F2CCQ28547386-38E36C19-6223-4FF1-972B-269B4C574DE7Q28660812-9E938FA9-FBA8-4F81-8799-F56A423A1F28Q33537452-5C0C22A6-6BFD-4960-9636-659EE894B5FCQ34134390-46C264CD-CF87-4EB7-9D76-5B5F288CA1DAQ34316771-2FB41474-FD27-457C-939F-366CEE25C4A9Q34609440-D1CE557B-F4D5-4BDC-A4C5-EA15A8376002Q34922937-C179ECAB-2F5A-4E87-BB01-778B100D24A8Q34976476-938E1962-D08F-45DF-BCEA-7898B9D6FEDEQ36854118-EAEB8EFA-D85E-4171-A672-3F8E258815B3Q37510953-FBC494A1-BA5A-499C-A119-053406EED6F3Q37605792-DAADE1B8-867F-4C35-8EA4-24337A39C1A8Q37763930-6BBCE33A-59BC-45B7-9645-44A168ECB8C0Q37863710-78FAE348-1E5B-4995-8FB1-27268A9B8820Q38008438-9230F94D-5EB9-485B-BFE1-BEE124F0D357Q38024403-88EE688F-65A4-4297-9D35-DFFB216E0153Q38026153-C8F38D3B-11D7-46E8-A597-B1E68978B3C6Q38033651-C9DB2317-50C7-44C9-A289-4C61CBAF28E9Q38037649-AF62B361-AA46-4C9D-AFA5-E14D5FED4A6BQ38054629-302E43AC-54BF-4477-887D-06AB406A6527Q38286229-30F40282-C461-49C4-B2F4-107CD93F3002Q38454015-2EB25064-A2DF-467E-BA6F-99E8DD466011Q38473846-31D045B5-BC7E-4E61-B135-A1204040F97AQ38886199-DB3FA81E-AB18-4865-ACF9-CF1506992368Q42392300-7C68FDFB-323F-49D6-91E3-E690E731CD7BQ42718095-A9E91BA7-0905-446B-8F86-81193501EA8FQ44309626-1CC14E4C-F353-4725-A17D-C2875D25313BQ51245240-1EEA35B5-F8F8-49AF-A6F2-2F1A66F88860Q53497512-0914435A-0092-40B4-A539-2AEFEF301B25Q54206970-BF176C18-8CE9-4D4C-A8EB-8878DE4A5A6AQ57223243-0AABE0FD-9535-4215-AA38-C9021F999AEDQ57302677-35ED9DF7-ED8A-4182-B0E9-7C33CF1FCC9A
P2860
Activation of T cells by carbamazepine and carbamazepine metabolites.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Activation of T cells by carbamazepine and carbamazepine metabolites.
@ast
Activation of T cells by carbamazepine and carbamazepine metabolites.
@en
Activation of T cells by carbamazepine and carbamazepine metabolites.
@nl
type
label
Activation of T cells by carbamazepine and carbamazepine metabolites.
@ast
Activation of T cells by carbamazepine and carbamazepine metabolites.
@en
Activation of T cells by carbamazepine and carbamazepine metabolites.
@nl
prefLabel
Activation of T cells by carbamazepine and carbamazepine metabolites.
@ast
Activation of T cells by carbamazepine and carbamazepine metabolites.
@en
Activation of T cells by carbamazepine and carbamazepine metabolites.
@nl
P2093
P50
P1476
Activation of T cells by carbamazepine and carbamazepine metabolites.
@en
P2093
Andrew V Stachulski
Anita Hanson
B Kevin Park
Dean J Naisbitt
Elizabeth Bowkett
Nicola S Drummond
Stephen E Clarke
P304
P356
10.1016/J.JACI.2006.03.005
P407
P577
2006-04-27T00:00:00Z